Controversies in the management of clinical stage 1 testis cancer
Can Urol Assoc J
.
2020 Nov;14(11):E537-E542.
doi: 10.5489/cuaj.6722.
Authors
Gregory J Nason
1
,
Peter Chung
2
,
Padraig Warde
2
,
Robert Huddart
3
,
Peter Albers
4
,
Christian Kollmannsberger
5
,
Christopher M Booth
6
,
Aaron R Hansen
7
,
Philippe L Bedard
7
,
Lawrence Einhorn
8
,
Craig Nichols
9
,
Ricardo A Rendon
10
,
Lori A Wood
11
,
Michael A S Jewett
1
,
Robert J Hamilton
1
Affiliations
1
Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, ON, Canada.
2
Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada.
3
The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
4
Department of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany.
5
British Columbia Cancer Agency Vancouver Cancer Centre, University of British Columbia, Vancouver, BC, Canada.
6
Cancer Care and Epidemiology, Cancer Research Institute, Queen's University, Kingston, ON, Canada.
7
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
8
Department of Oncology, Indiana University School of Medicine, Indianapolis, IN, United States.
9
Testicular Cancer Multidisciplinary Clinic, Virginia Mason Medical Center, Seattle, WA, United States.
10
Department of Urology, Dalhousie University, Halifax, NS, Canada.
11
Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
PMID:
32569575
PMCID:
PMC7673822
DOI:
10.5489/cuaj.6722
No abstract available